Evidence map›Paper›PMID 39424670›Full record

ArticleEuropean journal of human genetics : EJHG2025

Slowly progressive autosomal dominant Alport Syndrome due to COL4A3 splicing variant.

Sergio Daga, Lorenzo Loberti, Giulia Rollo, Loredaria Adamo, Olga Lorenza Colavecchio, Giulia Brunelli, Kristina Zguro, Sergio Antonio Tripodi, Andrea Guarnieri, Guido Garosi and 5 more

Erratum issuedAbstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. What's new in April's EJHG?European journal of human genetics : EJHG · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Sergio Daga *Medical Genetics, University of Siena, Siena, Italy.ORCID 0000-0002-6419-9456
Lorenzo Loberti *Medical Genetics, University of Siena, Siena, Italy.ORCID 0000-0001-5020-8393
Giulia RolloMedical Genetics, University of Siena, Siena, Italy.
Loredaria AdamoMedical Genetics, University of Siena, Siena, Italy.
Olga Lorenza ColavecchioGenetica Medica, Azienda Ospedaliero-Universitaria Senese, Siena, Italy.
Giulia BrunelliMedical Genetics, University of Siena, Siena, Italy.
Kristina ZguroMedical Genetics, University of Siena, Siena, Italy.
Sergio Antonio TripodiDepartment of Pathology, AOUS, Siena, Italy.
Andrea GuarnieriDepartment of Medical Sciences, Nephrology, Dialysis and Transplantation Unit, University Hospital of Siena, Siena, Italy.
Guido GarosiDepartment of Medical Sciences, Nephrology, Dialysis and Transplantation Unit, University Hospital of Siena, Siena, Italy.
Romina D'AurizioInstitute of Informatics and Telematics, CNR, Pisa, Italy.ORCID 0000-0002-1728-6397
Francesca ArianiMedical Genetics, University of Siena, Siena, Italy.
Rossella TitaGenetica Medica, Azienda Ospedaliero-Universitaria Senese, Siena, Italy.
Alessandra RenieriMedical Genetics, University of Siena, Siena, Italy. alessandra.renieri@unisi.it.ORCID 0000-0002-0846-9220
Anna Maria PintoGenetica Medica, Azienda Ospedaliero-Universitaria Senese, Siena, Italy. annamaria.pinto@dbm.unisi.it.ORCID 0000-0001-6259-6901

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alport syndrome is a rare genetic kidney disease caused by variants in the COL4A3/A4/A5 genes. It's characterised by progressive kidney failure, though therapies targeting Renin-Angiotensin System can delay its progression. Additionally, extrarenal manifestations may sometimes coexist. Recent advances in genetic analysis and the necessity to better clarify genotype-phenotype correlations in affected patients raises the importance of detecting even cryptic splicing variants, lying in both canonical and non-canonical splice sites variants such as last exonic nucleotide variants. These variants, often, do not cause an amino acid change but alter the snRNP proteins binding. We studied a big Italian family with Alport syndrome showing a clear dominant pattern of transmission with younger family members having only haematuria and older individuals presenting with End-Stage Kidney Failure (ESKF). Kidney biopsy showed the typical disease hallmarks. We deeply mined the data for SNV and CNV through exome sequencing on DNA from both peripheral blood samples and patients' podocytes-lineage cells. We identified an already reported synonymous variant, c.765G>A (p.(Thr255Thr)), in the last exonic nucleotide of exon 13 of the COL4A3 gene. Employing the patient's podocytes we demonstrated that this variant results in exon skipping leading to an in-frame deletion of 28 amino acids without leaky effect. According to the pattern of transmission, to the kidney biopsy and to the exome data analysis we provided further evidence that autosomal dominant Alport syndrome is a well-defined clinical entity. We also confirmed the pathogenicity of the synonymous COL4A3 variant for the first time demonstrating its role in a dominant pattern of transmission.

Indexed as

AutoantigensCollagen Type IVNephritis, HereditaryRNA SplicingAdultFemaleHumansMaleMiddle AgedPedigreePodocytesAutoantigensCollagen Type IVtype IV collagen alpha3 chain

Identifiers

PMID39424670
PMCPMC11985956

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.